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Mesenchymal stem-cell based therapies have been proposed as novel treatments for 
intervertebral disc degeneration, a prevalent and disabling condition associated with back 
pain. The development of these treatment strategies, however, has been hindered by the 
incomplete understanding of the human nucleus pulposus phenotype and by an inaccurate 
interpretation and translation of animal to human research. This review summarises recent 
work characterising the nucleus pulposus phenotype in different animal models and in 
humans and integrates their findings with the anatomical and physiological differences 
between these species. Understanding this phenotype is paramount to guarantee that 
implanted cells restore the native functions of the intervertebral disc.
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Introduction
Back pain is an almost universal symptom,
with its prevalence by lifetime, month and
time-point being 84%,1 23.2% and 11.9%,2
respectively. The economic impact of manag-
ing this condition and compensating for its
associated losses and disabilities accounts for
£12 billion annually in the United Kingdom3
and $85.9 billion in the USA.4
Although mechanical loading has been
frequently been implicated in the patho-
genesis of back pain,5-7 it is now known that
genetic predisposition may account for a sig-
nificant proportion of back pain associated
clinical conditions.1,8,9 Significantly, MRI has
shown that around 40% of patients with
back pain have associated degeneration of
the intervertebral disc (IVD),8,10 with a causal
relationship between both having been iden-
tified.11-13 IVD degeneration, as described by
Kirkaldy-Willis et al14 in their seminal work in
1978, triggers a cascade of events that lead to
most of the degenerative spinal conditions
treated in current clinical practice (disc bulg-
ing and herniation, spinal stenosis without
spondylolisthesis, spinal stenosis with
degenerative spondylolisthesis and degener-
ative scoliosis).14,15 Pain arising from disc
degeneration may be caused by inflamma-
tory responses triggered by degenerated
disc tissue herniating into the spinal canal,16
nerve ingrowth into the IVD itself following
annular and endplate ruptures,13,17 or due to
altered spine biomechanics.18
The IVD is responsible for shock absorption
and mobility of the spinal unit.19,20 It is com-
posed of a central nucleus pulposus (NP) and a
peripheral annulus fibrosus (AF), and is sepa-
rated from the vertebral bodies by two carti-
laginous endplates. The NP forms the
gelatinous inner core of the IVD. It comprises
large quantities of the proteoglycan aggrecan
within an irregular mesh of type II collagen
fibres. The AF is subdivided into outer AF,
which is formed by distinct lamellae, com-
posed of type I collagen fibres oriented
obliquely between each lamellae,21,22 and a
less fibrous and less organised inner AF, charac-
terised by a transition to type II collagen and
increased proteoglycan content.23 This archi-
tecture enables the AF to constrain the hydro-
static pressures generated within the NP upon
compression, facilitating mobility between the
spinal segments.24-27 The endplates are hyaline
cartilage structures that form the interface
between the IVD and the upper and lower
platforms of the vertebral bodies. They protect
the NP and AF inferiorly and superiorly and
allow diffusion of oxygen and nutrients to the
NP. Their structure is formed by a network of
type II collagen fibrils and proteoglycans.
Adjacent to the vertebral body the endplate is
richer in collagen, whereas adjacent to the NP
it is richer in proteoglycans.28
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The adult IVD is practically devoid of blood vessels,
being the largest avascular structure in the human body,
and, therefore, relies on diffusion through the endplate for
nutrient and oxygen supply. There is consequently a gradi-
ent of nutrient and oxygen availability from the peripheral
AF to the central NP, where nutrient and oxygen concentra-
tions are the lowest. As cells in the NP have to survive in
oxygen-deprived conditions, they rely mostly on glycolysis
to produce energy. In glycolysis, glucose is metabolised
into its waste product, lactic acid, which is removed from
the NP by diffusion through the endplate.29
NP cell morphology varies with age and maturation
and across different animal species. In humans, NP cells
are large and vacuolated at birth, similar to notochordal
cells from which they are derived, but a few years after
birth the NP becomes populated by smaller, round and
non-vacuolated cells, resembling articular cartilage (AC)
chondrocytes – for this reason they have been termed
chondrocyte-like cells.30 This change in cell morphology
has led to a long lasting debate regarding the origin of NP
cells. Some authors argue that notochordal cells die and
are replaced by chondrocyte-like cells migrating from
adjacent tissues,31-33 whereas others suggest that the
original notochordal NP cell population differentiates
into smaller chondrocyte-like cells.34-38 Significantly,
these differences in cell morphology are not common to
all animal species with some animals retaining cells with
notochordal morphology during most or even their
entire lifespan.19 These interspecies differences together
with the morphological similarity between human adult
NP cells and articular chondrocytes have frequently led to
an erroneous interpretation of NP cells as chondrocytes,
and to inaccurate interpretations of research derived from
animal studies.
Treatments for disc degeneration and the need 
for cell-based therapies
There is no definitive cure for disc degeneration and cur-
rent surgical treatments for disc degeneration-associated
conditions (such as herniation, stenosis or deformity) rely
on discectomy, spinal fusion and disc replacement. These
treatments, however, are associated with important com-
plications, such as degeneration of the spinal levels adja-
cent to the fused/replaced one39 and prosthesis-related
complications, such as migration into the adjacent verte-
bral body, extrusion and failure.40 More importantly,
these treatments address the disease symptoms and not
disease itself, failing to repair or regenerate the IVD.
Recent progress in tissue engineering and regenerative
medicine has increased the interest in developing a biolog-
ical approach to this disease, through which cells alone or
together with biomaterials would be implanted into the NP
to both repopulate and to stimulate native cells to produce
a healthier extracellular matrix. The promising clinical
results obtained in the treatment of osteoarthritis using
autologous chondrocyte implantation and matrix-induced
autologous chondrocyte implantation, in which autolo-
gous articular chondrocytes are harvested from non-
damaged AC areas, expanded ex vivo and re-implanted
(with or without a scaffold) into damaged osteo-arthritic
regions of joints,41,42 have led researchers to attempt a sim-
ilar strategy in the IVD. With this aim, dog IVD cells
expanded ex vivo and re-implanted into its discs were
shown to integrate and produce a cartilaginous extra-
cellular matrix43; these results have led to the initiation of
the Euro Disc Randomized Trial, an ongoing human clinical
trial.44 Implantation of autologous NP cells harvested from
degenerate discs may not be ideal, however, as degenerate
NP cells have an altered phenotype, with increased expres-
sion of senescence markers,45 increased expression of
matrix catabolic enzymes46,47 and decreased expression of
matrix components48,49 factors that would impair the abil-
ity of these cells to produce a healthy matrix.
A different approach would be to harvest cells from
non-degenerate discs. However, the method currently
used to harvest cells from healthy discs (disc needle punc-
ture) has been shown to induce degeneration.50-52 Alter-
natively, Nomura et al53 have proposed transplanting
allogenic NP tissue or cells. The use of such cells or tissue,
however, would require a donor bank of healthy human
samples, which would be difficult to obtain and could
pose immune rejection problems.
Stem cells, particularly mesenchymal stem cells, have
also been widely proposed as a source of cells in the treat-
ment of disc degeneration. A PubMed search including
the terms (‘intervertebral disc’ or ‘spinal degeneration’ or
‘disc degeneration’ or ‘degenerative disc disease’) AND
(‘stem cells’ or ‘stem cell’ or ‘mesenchymal cell’ or ‘stro-
mal cells’ or ‘MSC’) retrieved 261 papers, of which over
50% have been published in the last three years.
Mesenchymal stem cells are mesoderm-derived adult
stem cells, for which there is a growing body of evidence
confirming that they can be differentiated to adult NP
cells,37,54-62 suggesting they may be the ideal candidates
for novel cell-based therapies for disc degeneration.
Assessing stem cell differentiation: the 
importance of phenotyping the NP
For cell-based therapies to be successful, it is fundamental
that implanted cells have the correct phenotype to pro-
duce an appropriate functioning matrix in vivo. Stem cell
fate or differentiation can be influenced by co-culture,
growth factors and/ or biophysical conditions.63,64 How-
ever, in order to identify which differentiating factors
should be used and to assess the differentiation (particu-
larly the “end-stage” cell created), it is important to under-
stand the NP cell phenotype and specific cell markers.
To date, most of the studies assessing differentiation of
MSC to NP cells analyse differentiation and ‘end-stage’
cell phenotype using traditional chondrogenic genes,
such as collagen type II alpha 1 (COL2A1), aggrecan
(ACAN) and sex determining region Y (SRY)-box 9
IDENTIFICATION OF NOVEL NUCLEUS PULPOSUS MARKERS 171
VOL. 2, No. 8, AUGUST 2013
(SOX9),55,56,65-67 markers that are known to be expressed
by healthy adult human NP cells.49
However, while NP cells have some similarities with AC
cells, these cells and the tissues in which they reside have
considerable differences in terms of cell ontogeny, mor-
phology, matrix composition and biomechanical behav-
iour (Table I),68-71 and despite being important in the
tissue’s function, they have not been taken into account
when designing and assessing cell-based therapies for
disc degeneration. This is highlighted by the study by
Gorensek et al72 in which elastic cartilage from a rabbit’s
ear was transplanted into its IVD and shown to form a
solid tissue resembling AC, rather than a hydrated-gelati-
nous tissue like the NP. More recently, the relevance of
these differences to the tissue’s biology has led to a grow-
ing interest in identifying specific NP markers, character-
istic of its phenotype. Several years ago the proteins
hypoxia inducible factors 1 alpha and beta (HIF-1α and
HIF-1β), glucose transporter 1 (GLUT-1), matrix metallo-
proteinase 2 (MMP-2) and vascular endothelial growth
factor (VEGF) were shown to have higher expression in
the rat NP in comparison with its adjacent AF and cartilag-
inous endplate and thus, were proposed as NP-specific
markers.73,74 However, these molecules are associated
with responses to hypoxia and glucose starvation and
may correspond to an adaptation of NP cells to the
unique metabolic conditions NP cells have to withstand75
rather than marking a distinct cellular phenotype.
Consequently, a more thorough characterisation of
these cells was needed and, with recent advances in tran-
scriptomic profiling, the NP phenotype has now been
described in several species.
Analysing the NP phenotype: gene expression 
profiling
In molecular biology, gene expression profiling is the
measurement of the activity of genes being expressed by
a given cell in a specific moment. Extensive characterisa-
tion of these genes is permitted by the use of powerful
technologies, such as microarrays, ribonucleic acid
(RNA)-sequencing and chromatin immuno-precipitation
sequencing. The wide availability of microarrays has pro-
vided disease-related research with valuable transcrip-
tomic information on the interactions between cells and
the environment in which they reside with this informa-
tion being used to characterise disease states, predict dis-
ease progression and develop new therapies.76-78
In the IVD field, microarrays have been used to character-
ise and define the NP cell phenotype, particularly by high-
lighting differences between the NP and similar or
neighbouring tissues, such as AC, AF and endplate. Due to
the difficulty in obtaining human intervertebral disc tissue,
particularly non-degenerate, several of these studies have
used animal models. Furthermore, for safety reasons,
experimental treatments must be tested in animals and,
therefore, it is important to understand if disease mecha-
nisms differ between species and if/how they can be trans-
lated from animal research to human therapy.
Phenotyping studies have thus been conducted on fre-
quently used animal models, such as the rat,79-81 but also
animals whose IVD is thought to more closely resemble the
human, such as the dog82 and the bovine.36 More recently,
the human NP phenotype has also been assessed.37,83 
Results from these studies have provided new insights
into NP markers in different species, but also on funda-
mental aspects regarding the ontogeny, maturation and
degeneration of NP cells. As such, these findings have
important implications for the understanding of the
pathogenesis and treatment of disc degeneration and will
be the focus of the following sections of this review.
The rat nucleus pulposus. The rat is a frequently used
model for human diseases and has been extensively used
to understand disc degeneration.84-87 At birth, the rat NP is
populated by large vacuolated notochordal cells and this
population of cells is reported to be maintained during the
first 12 months of life, after which it starts to be replaced by
a smaller population of chondrocyte-like cells.88
Fujita et al79 have compared the transcriptome of the
rat NP (eight-week-old) with that of two avascular tis-
sues (AF and tendon), five mesenchymal tissues (skeletal
muscle, skin, blood, bone and bone marrow) and two
neurogenic tissues (spinal cord and brain). This compar-
ison, however, failed to include the AC, which, as afore-
mentioned, is the tissue that more closely resembles the
NP. The authors identified cluster differentiation 24
(CD24), a cell adhesion glycoprotein expressed at the
surface of B-lymphocytes and differentiating neuro-
blasts, as a cell surface marker with significantly higher
expression in the NP than in the other tissues analysed.
Table I. Main differences between articular cartilage and nucleus
pulposus
Characteristics Articular cartilage Nucleus pulposus
Cell ontogeny34,35 Lateral plate mesoderm Notochord (axial 
mesoderm)
Cell morphology Small and round Variable between 
species. In humans, they 
are large and vacuolated 
at birth, becoming small 
and round with matura-
tion/degeneration
Extracellular matrix 
proteoglycans68
Large aggregates 
(hyaluronic acid and 
central filaments), 
multiple monomers and 
large non-aggregated 
monomers
Short non-aggregated 
proteoglycan 
monomers and clusters 
of monomers without 
apparent central 
filaments
Aggrecan/type II 
collagen ratio69
2/1 27/1
Collagen network70 Rigid Loose
Biomechanical 
behaviour71
Viscoelastic solid in 
response to shear 
transient and dynamic 
deformation 
Fluid under transient 
and of a viscoelastic 
solid under dynamic 
deformation
Mechanical loads 
experienced71
Compressive loading Compressive and shear 
loading
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Additionally, CD24 immunopositivity was shown to be
present in six out of seven human chordomas (a noto-
chord-derived bone tumour found in the spine) but not
in chondrosarcoma samples.79
In a more recent study, Tang et al81 compared the NP
and AF gene expression and again identified CD24, but
also brain abundant membrane attached signal protein
(BASP1), N-Cadherin (N-Cad), neuropilin (NRP-1), CD155
and CD221 as specific rat NP markers. Interestingly, CD24
has also been shown to be expressed by NP cells from six-
to 17-year-old patients undergoing scoliosis surgery, hav-
ing been proposed as an immature human NP-marker.89
In another rat phenotyping study, Lee et al80 identi-
fied annexin A3 (ANXA3), glypican 3 (GPC3), keratin 19
(KRT19) and pleiotrophin (PTN) as highly differentially
expressed NP markers genes (compared with the AF and
AC), with KRT19 and GPC3 differential expression being
confirmed at the protein level. CD24, which had been
proposed by Fujita et al79 as a NP-specific cell surface
marker was also found to be highly differentially
expressed in the NP, but failed to meet the criteria of at
least five-fold differential expression used in this study.
GPC3, KRT19 and PTN are all involved in tissue develop-
ment and differentiation, with KRT19 in particular being
expressed by the human embryonic notochord90 and
chordoma.91 Interestingly, KRT19 expression in the rat
NP is not restricted to the notochordal cell-rich NP and
has also been found in adult (two-year-old) rat NP,
where large vacuolated notochordal cells were reported
to be absent.80
Stressing the importance of distinguishing the NP from
the AC, this study found that the gene procol2a1, which
codes for COL2A1, the predominant collagen type in NP
and AC, although being highly expressed in both tissues,
had five times higher expression in the AC,80 supporting
the more rigid nature of the AC compared with the more
gelatinous NP.
Despite being a commonly used animal model for disc
degeneration, findings from studies in the rat may not be
directly translatable to human research, as there are con-
siderable cellular and microenvironmental differences
between the IVD in both species. Being small quadru-
peds, the load applied to the rat spine is substantially
smaller than the load applied to the human spine.92 Addi-
tionally, as the human IVD cross-sectional area is signifi-
cantly larger than the rat’s, and since nutrient intake and
waste product removal from the NP are made through
diffusion from the endplate,29 it is possible that the
human NP is subjected to much more stressful conditions
(e.g. glucose starvation, hypoxia and acidic pH) than the
rat NP. Most importantly, rats retain morphologically dis-
tinct notochordal cells during at least half of their lifes-
pan, whereas such cells disappear from the human NP
soon after birth. These differences may have a consider-
able impact on the NP phenotype and on the translation
of these findings to humans.
The canine nucleus pulposus. Another animal frequently
used to study disc degeneration, particularly in NP
phenotyping studies, is the dog.93-96 Dogs are larger
quadrupeds and have a larger IVD than rats. Additionally,
similar to humans, certain breeds of dogs – such as the
dachshund, the beagle, the bulldog and the basset
hound (together named chondrodystrophoid dogs) – are
reported to lose their notochordal cells soon after birth;
these species then undergo spontaneous disc degenera-
tion.93,97 These aspects make these dog species poten-
tially more suitable as a model for human disc
degeneration.
Sakai et al82 performed comparative microarray analy-
sis between the NP and AF from 16- to 18-month-old bea-
gles and further analysed the identified molecules at the
gene and protein level in NP, AF and AC from the same
animals. Among the identified markers, α-2-macroglobu-
lin (A2M), keratin-18 (KRT18) and neural cell adhesion
molecule (NCAM1) were identified as highly expressed in
the NP compared to the AF and AC and desmocolin-2
(DSC2) compared with the AF. The high differential
expression of A2M in the aggrecan-rich dog NP may
account for its biological function – A2M has been shown
to be a potent inhibitor of the aggrecanases ADAMTS-4
and -5,98 two aggrecanases implicated in NP matrix deg-
radation.46,99 NCAM1 (CD56) and DSC2 are two cell sur-
face markers involved in cell-cell adhesion and interaction
but their specific function in the dog NP remains to be
explained. Like the rat NP marker KRT19, KRT18 has also
been identified in human notochordal cells during
development90 and also in the human NP.100,101
Of relevance is also the fact that this study identified
significant differences between the dog and the rat NP
phenotype. From the previously reported rat NP markers
(ANXA3, GPC3, KRT19, PTN and CD24) only GPC3 was
detected in this study and, contrary to the rat, it showed
higher expression in the AF than in the NP. These differ-
ences in gene expression between species are possibly a
reflection of the differences in the different cellular and
biochemical environment in the NP of these two species.
The bovine nucleus pulposus. The finding that there are
significant variations between the NP phenotype of differ-
ent species triggered the search for the NP phenotype in
other species, which would more closely resemble the
human NP. Bovine caudal discs have been widely used as
a model to study the human IVD.51,65,102,103 The IVD and
the endplate of both species have been reported to have
similar diameters and thicknesses and, due to the cow
tail’s musculature, to be submitted to similar biomechan-
ical forces.92 In terms of cellular population, the adult
bovine NP predominantly contains a large population of
small chondrocyte-like cells, although some authors have
described a coexistent small population of large vacuo-
lated notochord cells in animals aged < 30 months.19,36
A comparative microarray analysis was performed on
bovine NP, AF and AC,36 which identified and further
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validated KRT8, KRT18, KRT19, N-Cad, synaptosomal-
associated protein 25 (SNAP25) and sclerostin domain
containing 1 (SOSTDC1) as specific NP markers; BASP1,
KRT8, KRT18, tenomodulin (TNMD), TNF alpha induced
protein 6 (TNFAIP6), N-cad, forkhead box F1 (FOXF1),
forkhead box F2 (FOXF2), aquaporin 1 (AQP1), SOSTDC1
and SNAP25 as specific IVD (NP and AF) markers; and
integrin binding sialoprotein (IBSP) and fibulin 1 (FBLN1)
as negative NP markers. Confirming the interspecies vari-
ations that had been suggested in the canine array,82 this
study failed to identify any of the rat NP markers GPC3,
ANXA3, VIM, COMP, PTN and MGP or canine NP markers
A2M, ANXA4, DSC2, NCAM1 as bovine NP markers.36
In an attempt to address the transcriptional profile of
markers related to the unique IVD microenvironment,
Minogue et al36 investigated the expression of previously
identified rat microenvironment-related NP markers
(MMP-2, HIF1A, GLUT-1 and VEGF) in bovine tissues, hav-
ing failed, however, to identify significant differences
between their gene expression in the bovine NP and AC.
Although these differences may again be related to signif-
icant interspecies variations, it is of important note that
these markers were originally identified by changes in
protein expression and, therefore, the lack of differences
in the bovine transcriptome may also be due to post-
translational regulation or protein degradation, altering
protein half-life, which would not be reflected at the
mRNA level.104,105
Interestingly, the only common genes to the bovine NP
phenotype and other species were KRT18 (dog NP
marker), KRT19 (rat NP marker), KRT8 (rat NP marker
identified by Lee et al80 but not chosen for qRT-PCR vali-
dation) and N-Cad (rat NP marker).
The human nucleus pulposus. The aforementioned tran-
scriptional profiling studies were the first to provide a
comprehensive list of NP markers for each specific spe-
cies. They highlighted, however, the profound inter-
species variations in gene expression, which possibly
reflect differences in tissue and cell organisation, IVD and
spine size and biomechanics and different local physico-
chemical environment in each species. This emphasised
even more the need for the identification of the human
NP genetic signature.
Such a study was recently performed by Minogue et al.37
Using a stringent criteria of 20-fold differential expression
between the human NP and AC, the authors identified and
validated FOXF1, ovostatin 2 (OVOS2), haemoglobin beta
chain (HBB), carbonic anhydrase XII (CA12) and paired box
1 (PAX1) as specific human NP markers (compared with
AC), and growth differentiation factor 10 (GDF10), integrin
binding sialoprotein (IBSP) and cytokine-like 1 (CYTL1) as
specific human AC (NP-negative) markers.37
PAX1 is a transcription factor expressed by the develop-
ing sclerotome and involved in the Shh-dependent
mesenchymal-epithelial transition seen during the migra-
tion of sclerotomal cells towards the midline.106 The role of
FOXF1 in the intervertebral disc has been less studied but
recent findings have shown an association between dele-
tions in the FOXF1 gene and the VACTERL association, a
non-random association of birth defects which includes
spinal malformations and fusion of spinal vertebrae.107
The high differential expression of HBB and CA12 is pos-
sibly related to the adaptive mechanisms of the NP cells to
the harsh niche in which they reside. Haemoglobin, an oxy-
gen transport metalloprotein – usually found in erythro-
cytes – has recently been identified in neurons,
macrophages, alveolar cells and mesangial kidney cells
where it has been proposed to act by storing oxygen under
hypoxic conditions108-110; its identification in the hypoxic
NP may represent a similar homeostatic mechanism. As NP
cells have to survive in oxygen-deprived conditions, they
rely mostly on glycolysis to produce energy and produce
lactic acid as an end product; the accumulation of lactic
acid in the NP leads to an acidic environment.111,112 CA12 is
an enzyme that catalyses the conversion of carbon dioxide
and water to bicarbonate and protons and is important in
maintaining acid-base equilibrium by transporting carbon
dioxide from cells residing in acidic environments113;
together with CA9, it has also been identified in the devel-
oping IVD.114 It is possible that its presence in the human
NP serves to counteract the accumulation of acidic waste
products in this tissue.
Again, these results demonstrate high variability
between species. From the previously identified rodent
NP markers, only KRT19 and GPC3 showed a similar trend
in the human arrays (higher differential expression in NP
compared with AC); from the identified canine markers, a
similar trend was found for DSC12, KRT18 and NCAM1;
from the previously identified bovine markers, FOXF1 and
FOXF2 were the only genes with at least two-fold differ-
ential expression between the two human tissues.
Among the negative markers previously identified, the
bovine markers IBSP (80-fold differential expression
between both human tissues) and FBLN1 (qRT-PCR data)
were also validated as negative human NP markers.
More recently, Power et al83 used a similar strategy to
identify the human NP phenotype, and particularly NP-
specific genes containing transmembrane domains, in
comparison with the AF and AC. The rational for this
strategy was, besides adding to information about the
human NP phenotype, to identify potential NP-specific
cell surface markers, which could be used to target spe-
cific cells with nanoparticles and, thereby, systemically
delivering potential therapies to the NP cells.83 However,
it should be noted that for such a strategy to be accom-
plished, the NP would have to have sufficient blood
inflow to receive those particles, and the identified
markers should not be expressed by any other cell in the
human body, therefore assuring that the nanoparticles
would only target NP cells. Surprisingly, the array data
showed high similarity between the NP and the AF tran-
scriptome and failed to identify a differentially expressed
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transmembrane-containing domain gene between both
tissues. However, the comparison between NP and AC
identified a list of 28 potential candidates, and their val-
idation by qRT-PCR identified CA12 as the most signifi-
cantly differentially expressed gene between the three
tissues,83 adding strength to the importance of this acid-
base regulator in the highly acidic NP niche.
Gene profiling provides clues for NP ontogeny
Results from these studies provide valuable information
about the cellular population and the gene markers to be
used in IVD research. Importantly they highlight that
many of the markers are not common to all species and
that, although they can be used for research in a specific
animal model, they may not be suitable for translation to
the human IVD in health and disease. Interestingly, they
also highlight a significant overlapping gene profile
across species for some of the identified markers. Of note,
the following genes were found to have at least a two-fold
differential expression between NP and AC or AF cells in at
least two species: KRT8 (murine and bovine), KRT18
(murine, canine and human), KRT19 (murine and
human), FOXF1 (bovine and human), BASP1 (rat and
bovine) and N-Cad (rat and bovine) and may thus repre-
sent a common gene profile signature across these spe-
cies (Table II).
Keratins comprise the largest subfamily of intermediate
filaments proteins, proving structural support to the
nucleus and tensile strength to the cell, but are also
involved in more dynamic processes such as osmolarity
regulation, protein synthesis, mitosis, cell movement and
differentiation.115 Although keratin expression is tradi-
tionally indicative of an epithelial phenotype, its expres-
sion has been reported in mesoderm-derived cells, such
as cardiomyocytes,116 fibroblasts117 and the human foetal
notochord.90
Importantly, keratin expression in the NP provides clues to
the ontogeny of the NP cells, which has been a subject of a
long lasting debate. This controversy has been clarified by
recent fate-mapping studies in mice where the embryonic
notochord was shown to give rise to all the cells populating
the adult mice NP.34,35 However, it was still not clear why the
NP of some species lacks cells with a notochordal morphol-
ogy. In order to further investigate the expression of keratin
and also brachyury (also known to be expressed by noto-
chordal cells118,119) in animals where notochordal cells are
either absent or present in small numbers, we have isolated
two subpopulations of bovine NP cells – large vacuolated
and small chondrocyte-like (Fig. 1). Analysis of these two cell
populations showed that, although these notochordal
markers were highly expressed in larger cells, they were still
very highly expressed in small chondrocyte-like cells, and
that large cells share the expression of the chondrogenic
markers (SOX9, COL2A1 and ACAN) with small NP cells
(Fig. 2). This, together with the fact that keratins are
expressed in the NP of all the animal species assessed to date,
independently of the resident NP cell morphology, suggests
that large vacuolated and small chondrocyte-like cells may
all share a same notochordal lineage and that, contrary to
what has been postulated, notochordal cells do not disap-
pear but differentiate to smaller non-vacuolated cells. This
supports previous findings of rabbit notochordal cells differ-
entiating to chondrocyte-like cells as a response to injury.33
Gene expression variations with degeneration
The identification of the novel NP markers has given not
just a more comprehensive gene signature of the NP, but
also triggered an interest as to whether this gene expres-
sion varies with ageing and disc degeneration.
Using the spontaneous dog model of disc degenera-
tion (chondrodystrophic dogs), Smolders et al120 recently
identified a down-regulation of genes involved in Wnt
signalling and caveolin-1 occurring during the transition
from a notochordal-rich to a chondrocyte-like-rich NP
seen during early disc degeneration in these animals. The
Table II. List of identified nucleus pulposus markers
Rat* Dog* Bovine* Human*
KRT19†‡ A2M KRT8†‡ FOXF1†
GPC3 KRT18†‡ KRT18†‡ OVOS2
ANXA3 NCAM1 KRT19†‡ HBB
PTN DSC2 N-Cad† CA12
CD24 SNAP25 PAX1
KRT8†‡ SOSTDC1 KRT18†‡
N-Cad† FOXF1† KRT19†‡
FOXF2
* KRT, keratin; GPC, glypican; ANXA3, annexin a3; PTN, pleiotro-
phin; CD24, cluster differentiation 24; N-Cad, N-Cadherin; A2M, α-
2-macroglobulin; NCAM, neural cell adhesion molecule; DSC,
desmocolin; SNAP, synaptosomal-associated protein; SOSTDC1,
sclerostin domain containing protein 1; FOXF1, forkhead box F1;
OVOS, ovostatin; HBB, haemoglobin beta chain; CA12, carbonic
anhydrase XII; PAX1, paired box gene 1 
† indicates genes that have been identiﬁed in at least two different
species 
‡ indicates genes that indicate a notochordal ontogeny to the
nucleus pulposus cells
Fig. 1
Haematoxylin and eosin staining of bovine nucleus pulposus tissue, showing
small chondrocyte-like cells (arrows) coexist with large vacuolated noto-
chordal cells (magnified area).
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authors hypothesised that regulation of the Wnt pathway
and of caveolin-1 expression in the IVD may be a thera-
peutic target for treatment of disc degeneration.120
In humans, a comparison between normal and degen-
erate NP samples has shown that with degeneration there
is an alteration of the NP cell phenotype, with down-
regulation of the expression of NP markers SNAP25, KRT-8,
KRT-18 and N-Cad.36 This change has been confirmed by
Weiler et al,101 who showed decreased immunopositivity
for keratins and also galectin-3 with degeneration,
although failing to distinguish between KRT8 and KRT19
immunopositivity. The decreased levels of SNAP25, KRT-8,
KRT-18 and N-Cad with degeneration suggests that these
may be markers of a healthier phenotype that are lost with
degeneration. Conversely, KRT-19 and brachyury expres-
sion has been shown to remain unchanged with degener-
ation,36,121 which could then represent a stable NP
signature throughout degeneration. Immunopositivity for
CA12 was found to be high in the human immature NP,
lower in the adult non-degenerate NP and higher with
increasing degrees of degeneration, with its higher expres-
sion being proposed to correlate with the high metabolic
developmental processes and as a response to injury.83
Interestingly, the AF marker FBLN1 was found to be sig-
nificantly up-regulated in the NP of degenerate discs,36
which is in agreement with recent findings of AF cell
migration to the NP during degeneration.122
These data support previous evidence that with human
NP maturation, ageing and degeneration, the initial pop-
ulation of large, vacuolated notochordal cells does not
disappear, but instead differentiates to a population of
smaller chondrocyte-like cells; these morphologically
distinct cells display some differences in their gene
expression profile, but maintain the expression of genes,
such as KRT19 and brachyury. This concept is supported
by the findings of Yang et al,38 where the onset of degen-
eration was shown to coincide with differentiation of
mouse notochordal to chondrocyte-like cells; however,
the expression of putative NP or notochordal marker
genes was not determined in this study.
Future perspectives
Transcriptional profiling of the NP has provided invalu-
able information that can help to establish the NP pheno-
type in various species. Researchers in the IVD field have
now a library of specific genes that can be used to assess
the NP phenotype, some of which are common to differ-
ent animal species.
Additionally, the bovine and human studies have re-
ignited a debate that had been ongoing for decades con-
cerning the fate of notochordal cells in the NP of these spe-
cies. Evidence now supports the premise that these cells do
not disappear but rather differentiate to chondrocyte-like
cells. Interestingly, some of the markers reflecting the noto-
chordal ontogeny are also those that are common across
species (KRT8, KRT18, KRT19 and brachyury). Conversely,
other NP markers, such as HIF-1A, GLUT-1, HBB and CA12,
may thus reflect responses to the microenvironmental con-
ditions to which the NP cell is exposed to in each species.
As is norm in research, every scientific advance unveils
undiscovered fields that warrant future research. It is yet to
be clarified why in some animals NP cells maintain a noto-
chordal morphology throughout life, whereas in others
they differentiate to morphologically distinct cells. Addi-
tionally, is it not clear how homogeneous the small
chondrocyte-like population of adult NP cells is. A recent
report suggests that the expression of notochordal markers
is restricted to subpopulations of the adult NP123 and that
the non-notochordal population of NP cells may have
migrated from the AF to the NP in response to degenerative
stimuli.122 If so, it can be hypothesised that the elongated
fibroblastic AF cells adopt a round chondrocyte-like mor-
phology in response to the loose collagen network and
high proteoglycan content in the NP, as opposed to the
more ordered, fibrous matrix found in the AF. If this holds
true, it remains to be shown whether these cells display dif-
ferent metabolism, response to injury, catabolic and ana-
bolic properties. The identification of specific AF markers
and, hence its phenotype, would allow identification of AF-
derived cells with an NP-like morphology within the NP.
In respect to the treatment of intervertebral disc degen-
eration, particularly a cell-based therapy, it is still not
know which phenotype should be targeted (young noto-
chordal or a more mature chondrocyte-like). Understand-
ing this is fundamental to guarantee that implanted cells
have a NP phenotype capable of producing an appropri-
ately functioning hydrated tissue that may regenerate
and restore the functions of the intervertebral disc.
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Fig. 2
Bar chart showing the quantitative real-time polymerase chain reaction for
chondrogenic marker genes in separated bovine small chondrocyte-like and
notochordal cells. The mean relative gene expression for the chondrogenic
marker genes sex-determining region Y (SRY)-box 9 (SOX9), type II collagen
(Col2A1) and aggrecan (ACAN) was normalised for the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and plotted on a log
scale (* p < 0.05). Error bars denote the standard error of the mean.
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